Such combination therapy is predominantly focused on p53-deficient cancer cells as Tp53 mutation causes G1 checkpoint impairment [35] therefore leaving cancer cells to rely on G2 checkpoint for DNA repair and survival. Here, TP53 is linked to cancer.